J&J receives complete response letter for Xarelto

Johnson & Johnson (NYSE:JNJ) said it received a complete response letter from FDA for a sNDA for Xarelto rivaroxaban to reduce the risk of cardiovascular events in patients with acute coronary syndrome (ACS). J&J, which did not disclose details of the letter, said it is working with FDA to address the agency's requests. ...